GliaPharm has developed a proprietary technology platform, GliaXTM, to identify drugs that target glial cells’ activity and brain energy metabolism.
- Proprietary high throughput screening (HTS) technologies based on enzymatic and primary cell activities.
- A number of metabolic tests to characterize compounds in vitro (primary brain cells cultures) and in vivo (rodent’s brain).
- Different rodent models of neurological pathologies, including brain ageing, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and several psychiatric diseases.
- Different additional aspects of drug development and regulation are performed through selective contract research organizations (CROs).
GliaXTM platform not only serves GliaPharm’s in-house drug development, but is also used through collaborations with academic and industrial partners.